Hyperammonemia clinical trials
The registry lists 25 studies for Hyperammonemia across more than 10 countries. 3 are recruiting or about to start. 5 of them are mainly about Hyperammonemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Hyperammonemia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Amgen (6) · Mendel Tuchman (2) · TenNor Therapeutics (Suzhou) Limited (2) · iECURE, Inc. (2) · Uta Lichter-Konecki (1) · Nicola Longo (1) · Liminal BioSciences Ltd. (1) · Children's Mercy Hospital Kansas City (1)
What is being tested here
Drugs under test in Hyperammonemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 2 Hyperammonemia studies recruiting now, 1 (50%) set no upper age limit and 1 (50%) stop at 75 or younger. 2 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 1 (50%) | 1 (50%) |
| 30 | 1 (50%) | 1 (50%) |
| 40 | 1 (50%) | 1 (50%) |
| 50 | 1 (50%) | 1 (50%) |
| 65 | 1 (50%) | 1 (50%) |
| 75 | 1 (50%) | 1 (50%) |
| 85 | 1 (50%) | 1 (50%) |
Across all 25 studies, recruiting or not: 68% stop at 75 or younger and 56% at 65; 72% take children; 0% are for women only and 4% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 25 of 25. search them.
- Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)RecruitingNCT068056953 countries
- International Registry of Congenital Portosystemic Shunt (IRCPSS)Enrolling by invitationNCT0604190616 countries
- An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and PediatricsRecruitingNCT050401781 country
- An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC DeficiencyActive, not recruitingNCT06255782Phase 34 countries
- A Phase 1 Study to Evaluate PK Profile and Food Effects on PK Parameters of TNP-2092 CapsulesCompletedNCT06178718Phase 11 country
- PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With HyperammonemiaCompletedNCT06135675Phase 1/21 country
- Non-Cirrhotic Hyperammonemia Versus Hyperlactatemia in Septic Patients and Impact of TreatmentCompletedNCT067218451 country
- To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)CompletedNCT01257737Phase 42 countries
- Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)CompletedNCT01347073Phase 31 country
- Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle DisordersCompletedNCT00947544Phase 22 countries
- Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)CompletedNCT00947297Phase 32 countries
- Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle DisordersCompletedNCT00992459Phase 32 countries
- A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle DisordersCompletedNCT02246218Phase 42 countries
- Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRICompletedNCT01569568
- Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)CompletedNCT039470341 country
- Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia SyndromeCompletedNCT03797222Not applicable1 country
- A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium PhenylbutyrateTerminatedNCT05349435Phase 11 country
- Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)CompletedNCT01966419Phase 217 countries
- Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute HyperammonemiaCompletedNCT01599286Phase 21 country
- Blood Sugars in Children With Idiopathic Seizures.WithdrawnNCT002798511 country
- A Safety and Efficacy Study of Infusions of HepaStem in Urea Cycle Disorders Pediatric PatientsWithdrawnNCT03884959Phase 21 country
- N-Carbamylglutamate (Carbaglu) In The Treatment Of HyperammonemiaStatus unknownNCT00843921Phase 2/31 country
- Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young InfantsCompletedNCT01624311Phase 21 country
- Ammonia Levels and Cognitive ImpairmentTerminatedNCT020593561 country
- Anaplerotic Therapy in Propionic AcidemiaCompletedNCT00645879Phase 11 country